- Based upon preliminary analyses, cannabidiol (CBD) as an add-on drug for the treatment of pharmacoresistant epilepsy in a pediatric population does not appear to cause adverse effects involving cognition or adaptive function in patients who completed 1 year of treatment.
Why this matters
- Caregivers reported an overall improvement in quality of life (QoL).
- Participants (N=42) between the ages of 3 and 19 years with pharmacoresistant epilepsy were enrolled in an open label study of a pharmaceutical formulation of CBD (Epidiolex) as an add-on treatment of epilepsy by researchers at the University of Alabama at Birmingham.
- In addition to assessing several baseline medical variables, assessment of cognitive status and QoL was performed.
- After 1 year of participation in the trial, the participants were reassessed to determine if there had been any significant changes in cognition and general QoL.
- 24 participants remained in the study at 1-year follow-up.
- There were no significant changes in overall cognitive or functional adaptive status in the sample after 1 year.
- QoL was reported by caregivers as significantly improved (P<.05 with a mean increase of points in overall qolce score.>